focus -WSS

focus

author：fashion 2025-09-28 00:51:51 - browse：53165

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

WSS

Stanford president’s abrupt resignation sparks debate

Caribou posts encouraging results on off

US jobless claims fall again as labor market continues to flash strength

When a patient nears the end, a feared therapy can comfort

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Senator probes 340B programs at Cleveland Clinic, Bon Secours

entertainment

focus

focus

The high cost of giving birth even with insurance

When a patient nears the end, a feared therapy can comfort

Cancer drug shortages should be causing more outrage

Menendez indictment could see pharma lose a key ally

State Dept. review finds Biden bears some blame for Afghanistan failures

Ionis has late

After affirmative action ruling, medical educators look to 'holistic review'

Hormonal contraceptives don’t actually treat endometriosis

Apple is now the first public company to be valued at $3 trillion

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Wikipedia

WHO recommends dropping component of many flu vaccines

Address the ethical violations that led to 'Three Identical Strangers'

Telehealth startups are trying to fill the menopause care vacuum

FDA seeks to regulate lab

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Data show record exodus of life scientists from academia

hotspot

leisure time

hotspot

leisure time